ReShape Lifesciences, Inc. (OBLN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

NanoVibronix, Inc.

ReShape Lifesciences, Inc.

Nuwellis, Inc.

INVO BioScience, Inc.

Nexalin Technology, Inc.

Tivic Health Systems, Inc.

Bone Biologics Corp.

BIOLASE, Inc.

ThermoGenesis Holdings, Inc.

Motus GI Holdings, Inc.

Biocept, Inc.

Why is ReShape Lifesciences, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

The company has declared negative results in Mar'2025 after 2 consecutive positive quarters

INTEREST(9M) At USD 0.04 MM has Grown at inf%
NET SALES(Q) At USD 1.24 MM has Fallen at -30.76%
RAW MATERIAL COST(Y) Grown by 16.72% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -99.05%, its profits have risen by 44.3%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -99.05% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ReShape Lifesciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

ReShape Lifesciences, Inc.

-99.09%

-0.05

1970.76%

S&P 500

13.22%

0.96

19.87%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

19.93%

EBIT Growth (5y)

10.11%

EBIT to Interest (avg)

-17.12

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.03

Sales to Capital Employed (avg)

3.12

Tax Ratio

0.96%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.45%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.51

EV to EBIT

-0.09

EV to EBITDA

-0.09

EV to Capital Employed

-0.46

EV to Sales

0.08

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-501.25%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -7.7 MM

ROCE(HY)

Highest at -101.49%

NET PROFIT(9M)

Higher at USD -4.46 MM

DEBT-EQUITY RATIO (HY)

Lowest at -70.66 %

-18What is not working for the Company

INTEREST(9M)

At USD 0.04 MM has Grown at inf%

NET SALES(Q)

At USD 1.24 MM has Fallen at -30.76%

RAW MATERIAL COST(Y)

Grown by 16.72% (YoY

PRE-TAX PROFIT(Q)

At USD -1.91 MM has Fallen at -24.4%

NET PROFIT(Q)

At USD -1.92 MM has Fallen at -24.57%

Here's what is working for ReShape Lifesciences, Inc.

Operating Cash Flow

Highest at USD -7.7 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at -70.66 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for ReShape Lifesciences, Inc.

Interest

At USD 0.04 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales

At USD 1.24 MM has Fallen at -30.76%

over average net sales of the previous four periods of USD 1.79 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -1.91 MM has Fallen at -24.4%

over average net sales of the previous four periods of USD -1.54 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -1.92 MM has Fallen at -24.57%

over average net sales of the previous four periods of USD -1.54 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Raw Material Cost

Grown by 16.72% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales